The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Gipson cites safety concerns, as well as concerns that the tower will take up valuable event and parking space.

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

MUSC recieved updatesThe MUSC Board of Trustees received a key program update at the February board meeting on a ...

Step 1: Visit the official website of MAHACET at cetcell.mahacet.org. Step 2: On the homepage, look for the MAH B.Ed M.Ed CET ...